Glycitein
Catalog No: CFN99106
Gycitein has antioxidant, weak estrogenic, anti-invasion, and anti-proliferation activities, it has potentiol to prevent Abeta associated neurodegenerative disorders, and atherosclerotic cardiovascular diseases. It is a potent activator of ERK1/2, decreases RWPE-1 cell proliferation, it induces ERK1/2 activation was dependent, in part, on tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR).
Tormentic acid
Catalog No: CFN99434
Tormentic acid has anticancer, anti-inflammatory, anti-atherogenic , anti-allodynic, and hepatoprotective properties, it can inhibit markedly the neuropathic allodynia induced by partial ligation of the sciatic nerve. Tormentic acid potently inhibits the production of nitric oxide (NO) in RAW 264.7 cells, also suppresses the LPS-stimulated degradation and phosphorylation of inhibitor of kappa B-α (IκB-α), suggests that the anti-inflammatory activity of TA is associated with the down-regulation of iNOS, COX-2, and TNF-α through the negative regulation of the NF-κB pathway in RAW 264.7 cells.
Ergosterol peroxide glucoside
Catalog No: CFN99458
Ergosterol peroxide exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, anti-oxdiant, and anti-melanogenic activities. Ergosterol peroxide could as an anti-atherosclerosis agent, it exhibits hACAT-1 and Lp-PLA2 inhibitory effects, with inhibitory values of 51.6 +/- 0.9 and 51.7 +/- 1.2%, at a treatment concentration of 0.23 mM. Ergosterol peroxide has osteoclastogenesis inhibitory effect, it shows an inhibitory effect in a dose-dependent manner and an inhibition rate of up to 62% with low cytotoxicity, even at a concentration as low as 1.0 microg/mL.